KINASE INHIBITORS

Emerging real-world data from Japan shows that 4.9% of patients with EGFR-mutated non–small cell lung cancer treated with osimertinib monotherapy in one study experienced grade 3 or higher cardiac adverse events, including acute myocardial infarction, heart failure with left ventricular ejection fraction, and valvular heart disease.